Predicting response to neoadjuvant therapy with glucose transporter-1 in breast cancer.

Seda Duman Öztürk Çiğdem Öztürk Oguzhan Okcu Gokce Askan Bayram Sen Recep Bedir

Published in: Revista da Associacao Medica Brasileira (1992) (2023)

Glucose transporter-1 has the potential to be a biomarker that can be evaluated more objectively as an alternative to Ki-67 labeling index in evaluating the response to treatment in patients receiving neoadjuvant therapy.

Keyphrases

rectal cancer
locally advanced
lymph node
blood glucose
physical activity
type diabetes
radiation therapy
metabolic syndrome
adipose tissue
risk assessment
skeletal muscle
young adults
cell therapy
climate change
human health
smoking cessation
weight loss
childhood cancer